Avacincaptad pegol vs Cemdisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: Complement C5 · full Age-Related Macular Degeneration pipeline
Avacincaptad pegol · Izervay
Marketed by Astellas Pharma
NCT04435366 · Phase 3 · completed
This was a randomized, double-blind (participant, evaluating investigator, reading center, and sponsor masked), sham-controlled, parallel-group Phase 3 trial with 448 participants randomized to avacincaptad pegol or sham. The hard primary endpoint of geographic atrophy growth rate on fundus autofluorescence was met: avacincaptad pegol slowed GA enlargement compared with sham at Month 12 (LS mean 0.336 vs 0.392 mm/year; difference 0.056; 95% CI 0.016–0.096; p=0.0064), and both Month 24 co-primary comparisons also favored avacincaptad pegol. Secondary visual acuity and visual-function questionnaire endpoints did not show a significant benefit, but the primary structural endpoint was statistically significant.
Next expected readout: June 2027 · NCT06970665 (registry estimate)
Reported efficacy
The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12 (Baseline to month 12); The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24 (Baseline to month 24): 12-month geographic-atrophy growth: 0.336 vs 0.392 mm/year for avacincaptad pegol vs sham; difference 0.056 mm/year (95% CI 0.016 to 0.096; p=0.0064). 24-month geographic-atrophy growth: 2.23 vs 2.59 mm²/year for monthly avacincaptad pegol vs sham; difference 0.362 mm²/year (95% CI 0.066 to 0.657; p=0.0165). (met)
Result source: NCT04435366
Cemdisiran
Marketed by Alnylam Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2028 · NCT06541704 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Cemdisiran: no structured comparison results are available for Age-Related Macular Degeneration.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Avacincaptad pegol
show 2 more results
show 1 more result
show 1 more result
show 1 more result
Available safety results
Avacincaptad pegol
| Dropout rate | 11.1%Avacincaptad Pegol NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 show 11 more results—Avacincaptad Pegol Only (12 to 24 NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 —Avacincaptad Pegol Only (up to 12 NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 —Avacincaptad Pegol and Sham NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 —Avacincaptad Pegol and Sham Only ( NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 44.6%4 mg NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 28.6%2 mg NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 28%2 mg NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 15.4%1 mg NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 —EM NCT05536297 · Phase 3 · registry result, not featured evidence —EM NCT05536297 · Phase 3 · registry result, not featured evidence 16.4%EM NCT05536297 · Phase 3 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 1.3%Avacincaptad Pegol NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 show 11 more results—Avacincaptad Pegol Only (12 to 24 NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 —Avacincaptad Pegol Only (up to 12 NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 —Avacincaptad Pegol and Sham NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 —Avacincaptad Pegol and Sham Only ( NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 2.4%4 mg NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 2.4%2 mg NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 0%2 mg NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 0%1 mg NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 —EM NCT05536297 · Phase 3 · registry result, not featured evidence —EM NCT05536297 · Phase 3 · registry result, not featured evidence 4.6%EM NCT05536297 · Phase 3 · registry result, not featured evidence |
| Serious AEs | —Avacincaptad Pegol NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 show 11 more results18.8%Avacincaptad Pegol Only (12 to 24 NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 13.8%Avacincaptad Pegol Only (up to 12 NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 —Avacincaptad Pegol and Sham NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 17.2%Avacincaptad Pegol and Sham Only ( NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 25.3%4 mg NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 19%2 mg NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 16%2 mg NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 11.5%1 mg NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 21.9%EM NCT05536297 · Phase 3 · registry result, not featured evidence 21.3%EM NCT05536297 · Phase 3 · registry result, not featured evidence 15.9%EM NCT05536297 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | conjunctival haemorrhage 14.6% (placebo 2.5%) choroidal neovascularisation 11.5% (placebo 9.4%) covid-19 11.5% (placebo 12.8%) NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 show 9 more resultsconjunctival haemorrhage 13.8% (placebo 2.5%) intraocular pressure increased 9.8% (placebo 0.5%) choroidal neovascularisation 9.3% (placebo 9.4%) NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 covid-19 15.1% (placebo 12.8%) conjunctival haemorrhage 9.7% (placebo 2.5%) choroidal neovascularisation 8.6% (placebo 9.4%) NCT04435366 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 3 4 mg conjunctival haemorrhage * 33.7% (placebo 14.3%) intraocular pressure increased 22.9% (placebo 1.2%) neovascular age-related macular degeneration* 13.3% (placebo 2.4%) NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 2 mg conjunctival haemorrhage * 21.4% (placebo 14.3%) fall 19% (placebo 8.3%) neovascular age-related macular degeneration* 16.7% (placebo 2.4%) NCT02686658 · Phase 2/3 · combination · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 2 mg nasopharyngitis 12% (placebo 6%) conjunctival haemorrhage * 8% (placebo 14.3%) influenza 8% (placebo 1.2%) NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 1 mg neovascular age-related macular degeneration* 11.5% (placebo 2.4%) vitreous detachment* 11.5% (placebo 7.1%) cataract* 7.7% (placebo 6%) NCT02686658 · Phase 2/3 · monotherapy · Age-Related Macular Degeneration, Geographic Atrophy · phase 2/3 EM choroidal neovascularisation 15.6% fall 14.1% intraocular pressure increased 14.1% NCT05536297 · Phase 3 · registry result, not featured evidence EM cataract 16.4% intraocular pressure increased 16.4% conjunctival haemorrhage 9.8% NCT05536297 · Phase 3 · registry result, not featured evidence EM intraocular pressure increased 13.9% choroidal neovascularisation 13.2% visual acuity reduced 11.9% NCT05536297 · Phase 3 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Avacincaptad pegol's landscape · Cemdisiran's landscape